Triple
T10214621
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Renflexis |
E242409
|
entity |
| Predicate | hasReferenceProduct |
P62838
|
FINISHED |
| Object | Remicade |
E49851
|
NE FINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Remicade | Statement: [Renflexis, hasReferenceProduct, Remicade]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Remicade Context triple: [Renflexis, hasReferenceProduct, Remicade]
-
A.
Remicade
chosen
Remicade is a widely used monoclonal antibody biologic (infliximab) prescribed to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
B.
Humira
Humira is a widely used biologic medication (adalimumab) that treats various autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease by inhibiting tumor necrosis factor (TNF).
-
C.
Stelara
Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
-
D.
Kevzara
Kevzara is a prescription monoclonal antibody medication (sarilumab) used to treat adults with moderate to severe rheumatoid arthritis by targeting the interleukin-6 (IL-6) receptor.
-
E.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
PD
Predicate disambiguation
gpt-5-mini-2025-08-07
Target predicate: hasReferenceProduct Context triple: [Renflexis, hasReferenceProduct, Remicade]
-
A.
hasProduct
Indicates that an entity possesses, offers, or is associated with a particular product.
-
B.
hasRetailProduct
Indicates that an entity offers, sells, or makes available a particular product in a retail context.
-
C.
hasReferenceWork
Indicates that one entity is associated with a reference work (such as a dictionary, encyclopedia, or manual) that provides authoritative information about it.
-
D.
byProduct
Indicates that one entity is produced incidentally or as a secondary result of a process, activity, or creation involving another entity.
-
E.
relatedToProduct
chosen
Indicates a general association or connection between an entity and a specific product, without specifying the exact nature of that relationship.
- F. None of above.
Provenance (4 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d381ae26c48190985abd0e25ee5d04 |
completed | April 6, 2026, 9:49 a.m. |
| NER | Named-entity recognition | batch_69d3aa273bdc8190bc4cf67a7923cebc |
completed | April 6, 2026, 12:42 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69d89f25c16c8190a17dc19e3e1b197a |
completed | April 10, 2026, 6:56 a.m. |
| PD | Predicate disambiguation | batch_69d39559e5ac8190b88eca75956b7e6a |
completed | April 6, 2026, 11:13 a.m. |
Created at: April 6, 2026, 11:04 a.m.